Annexon ANNX 深 沪
已收盘 12-19 16:00:00 美东时间
5.17
+0.350
+7.26%
华盛通- 最 高5.415
- 今 开4.86
- 成交量 1046.05万股
- 最 低 4.85
- 昨 收 4.82
- 总市值 7.70亿
- 52周最高 5.66
- 市盈率 静 --
- 换手率 7.02%
- 52周最低 1.285
- 委 比 62.16%
- 总股本 1.49亿
- 历史最高 38.01
- 量 比 3.26
- 振 幅 11.72%
- 历史最低 1.285
- 每 手 1
- 风险率 0.99%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
Annexon, Inc. granted stock options to a new non-executive employee under its 2022 Employment Inducement Award Plan, approved on December 10, 2025. The employee received an option to purchase 19,000 shares with an exercise price of $4.91, vesting over four years. Annexon develops complement inhibitors targeting neuroinflammation caused by C1q activation, addressing autoimmunity, neurodegeneration, and ophthalmology diseases. Its mission is to del...
12-17 00:31
美股大行评级 | 最高500美元！MongoDB获18家大行紧急上调目标价；巴克莱下调理想汽车目标价至18美元
今日重点评级关注：B. Riley证券：维持Seabridge Gold"买入"评级，目标价从50美元升至65美元；HC Wainwright & Co.：维持TRX Gold"买入"评级，目标价从1.2美元升至1.4美元
12-03 09:58
Clear Street Initiates Coverage On Annexon with Buy Rating, Announces Price Target of $17
Clear Street analyst Bill Maughan initiates coverage on Annexon (NASDAQ:ANNX) with a Buy rating and announces Price Target of $17.
12-02 22:06
Annexon stock rises after director purchases shares
Annexon (ANNX) stock rose after the company's director disclosed a purchase of shares for an approximate value of about $5M. The stock is up about 15% today. Muneer Satter, director at Annexon, bought...
11-21 01:02
美股牛股 | 社交电商平台WeShop单日暴涨500%！Adobe宣布19亿美元收购SEMrush
社交电商平台WeShop单日暴涨500%！SEMrush股价大涨74%，获Adobe19亿美元收购；碳酸锂价格突破10万元大关！锂矿公司SGML再涨33%>>
11-20 16:31
美股大行评级 | 高盛上调百度、美敦力、晶科能源等多只个股目标价；家得宝遭9家机构下调目标价；
今日重点评级关注：富国银行：维持Annexon"超配"评级，目标价从14美元升至27美元；瑞穗：上调Relmada Therapeutics评级至"跑赢大市"，目标价从1美元升至10美元
11-20 10:28
Wells Fargo Maintains Overweight on Annexon, Raises Price Target to $27
Wells Fargo analyst Derek Archila maintains Annexon (NASDAQ:ANNX) with a Overweight and raises the price target from $14 to $27.
11-20 03:12
Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
Annexon, Inc. highlighted progress in its neuroinflammation platform, advancing therapies for Guillain-Barré Syndrome (GBS), geographic atrophy (GA) in dry AMD, and autoimmune diseases. Key milestones include the submission of the European Marketing Authorization Application (MAA) for tanr Pruittart in GBS by January 2026, potential first targeted therapy for GBS; topline results from the vonaprument Phase 3 trial in GA expected in late 2026; and...
11-10 21:05
纳斯达克生物科技指数收涨将近1.5%
成分股Applied Therapeutics收涨119.56%，Crinetics Pharma涨27.92%，Annexon涨20.79%表现第三。Kyv...
09-27 04:30
Annexon Biosciences to Participate in Upcoming September Investor Conferences
Annexon Biosciences (Nasdaq: ANNX) announced that CEO Douglas Love will participate in fireside chats at the Wells Fargo Healthcare Conference on September 3, 2025, and the Cantor Global Healthcare Conference on September 4, 2025. Live webcasts will be available on the company’s website, with replays archived for 30 days. Annexon is developing first-in-kind therapies targeting classical complement-driven neuroinflammation for neuroinflammatory di...
08-27 12:00
